GlaxoSmithKline plc (NYSE:GSK) released on Wednesday, a report disclosing its full financial year 2020 performance. The report revealed that the company had a good year regardless of the tough conditions caused by the pandemic.
The company reported strong sales totaling £3.1 billion during the year. About £17 billion of those sales came from the pharmaceuticals segment. The consumer healthcare segment generated £10 billion while vaccine sales amounted to £7 billion. GSK’s total operating margin for the year was 22.8%. Its total EPS for the year was 115.5p which represents a +23% increase at an annual equivalent rate.
The adjusted EPS was 115.9p and adjusted group operating margin was 26.1%. GSK reported net cash flow of £4 billion from its operations in Q4 alone. The free cash flow during the same period was £3 billion. The impressive performance was supported by new product launches which also highlight the company’s preparedness for the split of its consumer healthcare and biopharma businesses.
“2020 was an extraordinary year for all of us, and one of significant progress for GSK. We invested in our pipeline and new launches,” stated GSK CEO, Emma Walmsley.
GSK’s expanding product pipeline sets the stage for an interesting financial future
2020 was a good year for GSK’s product pipeline because the company received 9 product approvals, setting the stage for more revenue streams. The pharmaceutical giant is also excited about the next few years courtesy of more than 20 products that are in the pipeline and that are expected to hit the markets as soon as 2026. More than 10 of those developmental products are expected to generate more than $1 billion in annual revenues.
GSK has been ramping up its product pipeline especially in the oncology segment for which it has 15 products that are currently in trials. Three of them are cell therapies and 9 are immune-oncology therapies. The company is also building up a presence in gene therapies and antibody treatment through acquisitions that target those particular segments. GSK expects the investment measures to support continued strong growth moving forward.